Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. At least ≥50 years old, and~2. Systolic blood pressure (SBP): (having documentation of SBP to meet the criteria below on 2 consecutive visits)~   * SBP: 130-180 mmHg on 0 or 1 medication~  * SBP: 130-170 mmHg on up to 2 medications~  * SBP: 130-160 mmHg on up to 3 medications~  * SBP: 130-150 mmHg on up to 4 medications, and~3. Prior vascular disease or at high vascular risk~   1. Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), at least a 50% diameter stenosis of a coronary, chest pain with objective evidence of myocardial ischemia (load electrocardiogram or load image examination indicated myocardial ischemia)~  2. Previous stroke~  3. Carotid endarterectomy (CE), or carotid stenting~  4. Peripheral artery disease (PAD) with revascularization~  5. Abdominal aortic aneurysm (AAA) ≥5 cm with repair~  6. Combine with no less than two risk factors below~      * ≥60 years old male or ≥65 years old female~     * Diabetes~     * Dyslipidemia (total cholesterol \>200 mg/dL \[5.2 mmol/L\] or LDL-C \>130 mg/dL \[3.4 mmol/L\] or HDL-C \< 40 mg/dL \[1.0 mmol/L\])~     * Current smoking (smoke more than a cigarette every day in the past 12 months)~Exclusion Criteria:~1. Known secondary cause of hypertension~2. An indication for a specific BP lowering medication that the participant is not taking and the participant has not been documented to be intolerant of the medication class~3. One minute standing SBP \<110 mmHg (not applicable if unable to stand)~4. Arm circumference too large or small to allow accurate blood pressure measurement with available devices~5. Proteinuria defined as urine dipstick ≥2+ protein at screening~6. Glomerulonephritis treated with or likely to be treated with immunosuppressive therapy~7. eGFR \<45 ml/min /1.73m2 or end-stage renal disease (ESRD)~8. Previous MI, stroke, or hospitalization for angina, PCI, CABG, CE or carotid stenting, PAD with revascularization, AAA≥5 cm with repair within last 3 months~9. Symptomatic heart failure within the past 6 months or documented left ventricular ejection fraction (by any method) \<35%~10. PCI or CABG planned for the next 6 months~11. A medical condition likely to limit survival to less than 3 years, or a cancer (other than non-melanoma skin cancer) diagnosed and treated within the past two years that, in the judgment of local clinical investigators, would compromise a participant's ability to comply with the protocol and complete the trial~12. Any organ transplant~13. Pregnancy, breast-feeding, or of child-bearing potential and not using adequate contraception~14. Any factors judged by local clinic investigators to be likely to limit adherence to interventions. For example,~    1. Active alcohol or substance abuse within the last 12 months~   2. Plans to move to another place to live for a long time~   3. Clinical diagnosis of dementia or mild cognitive impairment (MCI)~15. Currently participation in a clinical trial with an unlicensed drug or device~16. Living in the same household as an already randomized participant

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive treatment group (Type: EXPERIMENTAL): Participants randomized into the Intensive treatment group will have a goal of SBP \<120 mmHg. A two- or three-drug regimen should be initiated at randomization for most participants. Drug doses should be increased and/or additional antihypertensive medications should be added at each visit in the intensive treatment group, usually at monthly intervals, until the participant's goal of \<120 mmHg has been reached or the local investigator decides no further antihypertensive medications may be added.
- Standard treatment group (Type: ACTIVE_COMPARATOR): Participants randomized into the Standard treatment group will have a goal of SBP \<140 mmHg. It is expected to achieve a SBP of 135-139 mmHg in as many participants as possible. Medication dose titration or addition of another drug is indicated if SBP is ≥160 mmHg at a single visit or is ≥140 mmHg at two consecutive visits. Down titration should be carried out if the SBP is \<130 mmHg at a single visit or \<135 mmHg at two consecutive visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).